Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
Tri Acetyl Azacitidine, 10302-78-0
Application Notes
Useful research chemical for a range of applications
Hazard Compound
No -Refer MSDS for accurate information
Tri Acetyl Azacitidine is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Tri Acetyl Azacitidine usage and description
Tri Acetyl Azacitidine, also known as TAAC, is a synthetic compound and a derivative of the chemotherapy drug Azacitidine. TAAC is used as an anti-cancer agent and is specifically used in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
The chemical structure of TAAC is similar to Azacitidine, but with three acetyl groups added to the nitrogen atoms. This modification helps to increase the stability of the compound and also improves its bioavailability. TAAC works by inhibiting the activity of DNA methyltransferase enzymes, which causes the re-expression of silenced tumor suppressor genes and the suppression of cancer cell growth.
TAAC is administered via injection into the bloodstream and is typically given as a 30-minute infusion once a day for five consecutive days in a 28-day cycle. The dosage is determined by the patient's body weight and other factors such as kidney function.
In clinical trials, TAAC has shown promising results in the treatment of AML and MDS, with some patients achieving complete remission or significant improvement in their condition. However, like most chemotherapy drugs, TAAC can cause side effects such as low white blood cell count, fatigue, and increased risk of infection.
In conclusion, TAAC is a potent anti-cancer agent that shows great potential in the treatment of AML and MDS. Its chemical structure and mechanism of action make it a valuable addition to the arsenal of chemotherapy drugs available for these diseases. However, further research is needed to fully understand its effectiveness and potential side effects.
